Drug intelligence / Profile preview

AP203

Development stage: Phase 2
Lead developer: AP Biosciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AP203 is an investigational drug developed by AP Biosciences Inc. It is currently being evaluated in a Phase 1/2 clinical study for its safety, pharmacokinetics, and clinical activity in adult patients with locally advanced or metastatic solid tumors. The drug is administered via intravenous infusion.

Targets

CD274 (Programmed cell death protein 1 ligand 1)TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on AP203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP203.

Explore the full profile